Moreover, the ChIP assay with the anti-BPTF antibody pulled down less VEGF promoter fragment (−1384 to −1667 region) in NSCLC cells with the increase in lumbrokinase treatment concentration (Figure 3D). Here, BPTF is linked to non-small cell lung carcinoma.